A single-step, competitive polymerase chain reaction technique was developed to quantitate sheep-associated malignant catarrhal fever (SA-MCF) viral DNA. The assay employed coamplification of a fixed quantity of target DNA with graded amounts of a competitor, generated by truncation of the target sequence lying between the 2 primer binding sites. The assay yielded a linear response (r ϭ 0.98) for DNA measurement within the range of 30-300,000 copies. Amplification efficiency analysis by coamplification of target and competitor in equal copy numbers for various numbers of cycles showed that the relative abundance of the coamplified products remained constant with increasing cycle numbers up to 40. Reproducibility was assessed by repetitively assaying a set of blind-coded samples from a variety of animals and tissues. Results indicated that the assay is reliable and reproducible for quantitation of SA-MCF viral DNA in samples from asymptomatically infected sheep and from animals with clinical SA-MCF.
Sheep-associated (SA) malignant catarrhal fever (MCF) is 1 of the 2 major epidemiologic types of the frequently fatal disease syndrome of certain ruminant species known as MCF. 11, 12 Although indistinguishable clinically or histopathologically, the 2 types are separated by an epidemiologic feature: the predominant carrier ruminant species in which the virus survives in nature. The causative agent of the SA entity exists as a subclinical infection in domestic sheep and in a number of exotic sheep species. This agent, however, has never been propagated in vitro. The analogous agent that is resident in wildebeest, known as alcelaphine herpesvirus-1 (AHV-1), can be readily propagated in vitro and is relatively well characterized. 2, 12, 13 It is classified within the herpes subfamily Gammaherpesvirinae. 14 The fact that the SA agent has never been successfully propagated has hampered studies into the etiology, epidemiology, and pathogenesis of this agent. It has nonetheless been named ovine herpesvirus 2 (OHV-2), based on limited base sequence comparison with AHV-1. 3, 14 Recent improvements in methods for detection of the genomic DNA of the SA virus have provided for improved accuracy in diagnosis of clinical MCF and enabled studies that are beginning to better define the epidemiology of this agent. 1, 6, 7 Accurate quantitation of both extracellular and intracellular viral DNA is essential to delineate shedding patterns, organ-specific virus loads, and other aspects of pathogenesis and epidemiology. The polymerase chain reaction (PCR) technique is a sensitive method for detecting DNA, which has been applied to detection of OHV-2 DNA. 6, 17, 19 It can be difficult, however, to obtain accurate measurements of DNA with conventional PCR for several reasons. For example, because of the exponential nature of PCR amplification, small variations in amplification efficiency can dramatically affect the yield of product. 5, 10, 20 Moreover, the nonlinearity of the reaction in the plateau region of the amplification curve further precludes precise quantitation based on simple measures of amplicon yield. 15 The competitive PCR (cPCR) technique is a sensitive and quantitative method for measuring DNA in biological materials. In this report, we describe the development and characterization of a cPCR for measurement of DNA of the SA-MCF agent and demonstrate its suitability for studies involving fresh tissues, blood cells, and nasal secretions.
Materials and methods
Sample preparation. DNA purification from fresh peripheral blood leukocytes (PBLs), nasal secretions, and tissues of MCF-virus-infected animals was based on standard methods. 8 Competitor generation. A fragment designed for use as a competitor in the PCR reaction was produced by amplification of a truncated version 4,18 of the 422-bp fragment of OHV-2 DNA that has been used in previous studies of SA-MCF. 1, 6 This truncated fragment was amplified from the originally described target sequence by modifying 1 of the members of the primer set originally designated 556-755. 1 The 755 primer was modified by addition of a 21-bp sequence (underlined below) to its 3Ј end that was homologous to a 21-bp sequence located 113 bp downstream of the original primer (755) binding site. The sequence of the hybrid primer (cP-1) was 5Ј-AAGATAAGCACCAGTTATGCATCTGA-TAAAATTAGAGCACAGGCCCGCTAC-3Ј. Amplification of the region between this hybrid primer and the other member of the pair, the 556 primer, yielded a competitive fragment of 309 bp with the original primer binding sites on each end, which easily can be distinguished in a gel from the original 422 bp amplicon. The fragment was cloned by a PCR direct cloning method as described by the manufacturer. a The plasmids containing the competitor were purified by CsCl density centrifugation. b, 8 Competitor calibration. After purification, the concentration of plasmid DNA was determined by OD 260 . The copy number of the plasmids containing the competitor was calculated from the DNA concentration and confirmed by comparing band intensity in agarose gels with a standard DNA mass marker. a To assess the accuracy of the competitor concentration and to further validate the assay, the full-length 422-bp target DNA fragment was also cloned by the same method. The plasmids containing the 422-bp target DNA fragment were purified and carefully quantitated. Serial dilutions of standardized solutions containing equal copy numbers of both the plasmids containing the competitor or the 422-bp target DNA were amplified, and the relative intensity of the bands were evaluated by densitometry. b To examine the dose-dependent relationship between the target and the competitor, a series of dilutions containing predetermined competitor numbers of 75-30,000 copies were amplified in the presence of a fixed amount of target DNA (1,500 copies). A regression line was calculated for the plot of the ratio between the densities of target/competitor bands and the corresponding competitor copy number.
PCR amplification conditions. The PCR amplification conditions were the same as previously described, 6 except that a 1-step, 40-cycle amplification regimen was used. To define the optimum number cycles for the cPCR reactions, a series of amplifications using graded numbers of cycles from 25 to 43 was performed. A 2-step PCR as described previously 6 was also used for quantitation of viral DNA in comparison with the conventional sample-dilution method with the cPCR.
Results
Linearity and amplification efficiency. A fixed copy amount (1,500 copies) of target was coamplified with serial dilutions of competitor containing 75-30,000 copies, and the resulting band intensities were measured by densitometry. The logs of the ratios between mean densities of the target and competitor bands when plotted against the log of the corresponding competitor copy number yielded a reasonably linear relationship (r ϭ 0.98) ( Fig. 1 ). Similar amplification rates between the competitor and target are a prerequisite for a quantitative competitive assay. 20 To assess amplification efficiencies, 4 sets of samples containing competitor and target at equal copy numbers (30, 300, 3,000, and 30,000 copies) were coamplified using various numbers of cycles (25, 28, 31, 34, 37, 40, and 43). The ratios between the band intensities varied little with increasing numbers of cycles up to 43, indi-cating that the efficiency of amplification of the target sequence and the competitor sequences were roughly equivalent (data not shown).
Sensitivity and reproducibility. The results of the series of amplifications allowed an estimate of the minimum threshold of sensitivity for the assay when used at different numbers of amplification cycles. The minimum numbers of copies necessary to yield clearly visible bands at a given number of cycles were 30,000 copies at 31 cycles, 3,000 copies at 34, 300 copies at 37, and 30 copies at 40 cycles. Increasing the cycle number to 43 yielded no further increase in sensitivity (data not shown).
Six samples were collected from nasal secretions and PBLs of a MCF-virus-infected sheep and from PBLs or tissues of 5 cases of clinical MCF in moose, axis deer, bison and cattle. DNA was extracted, and each sample was divided into 3 parts, blind coded, and quantified by cPCR. The variation observed between aliquots of the same sample when assayed at different times was very low (Fig. 2) .
Comparison with conventional dilution assay. The 40-cycle cPCR assay for quantitation of SA-MCF viral DNA was compared with both a 1-step, 40-cycle PCR and a 2-step (nested, both 34 cycles) PCR 6 used in a dilution assay, wherein the DNA samples were diluted to end points (log 10 ) prior to amplification. There was close agreement between the competitive assay and the target dilution assay for 9 of 15 samples. For the other 6 samples, the cPCR yielded a slightly higher number (Table 1) .
Discussion
A cPCR assay was used for quantitating SA-MCF viral DNA in clinical specimens. The assay was a 1step, 40-cycle coamplification of target and competitor. The minimum threshold of sensitivity was 30 copies of the viral genomic DNA. Although acceptable bands were sometimes obtained with Ͻ30 copies, results were not consistent below that level. The maximum accurately quantifiable level was about 300,000 copies. Samples with higher copy numbers should be diluted to maximize accuracy.
The assay was essentially linear over the working range. Trials showed that increasing the number of cycles beyond 40 yielded no practical benefit in sensitivity. Comparison with a nested (2-step) PCR yielded almost the same sensitivity in the 2 methods, the nested procedure having only the advantage of more stable band densities that did not diminish significantly with decreasing target copy number as did the bands from the 1-step protocol. Although this phenomenon can lead to difficulty in interpreting gels at very low copy numbers, this problem should not be significant for most uses, particularly diagnostic purposes. Most sam- Figure 1 . A fixed amount of target DNA coamplified with different concentration of competitors by PCR. A. Agarose gel electrophoresis of PCR products from 1,500 copies of target DNA coamplified with 30,000, 15,000, 7,500, 3,000, 1,500, 750, 300, 150, and 75 competitors (lanes 1-9) . B. The regression line of the data points obtained when the log of ratios between the mean band density of target and competitor were plotted against the log of corresponding copy number of competitor. ples from clinically ill animals and from asymptomatic carriers far exceed the 30-copy threshold below which indistinct bands can be difficult to interpret.
In cPCR assays, the differences in amplification efficiency due to variation in length and base composition between target and competitor can be a source of significant error. 5, 9 In this study, the competitor was generated by deleting 113 bp from the 422-bp target DNA sequence, yielding an amplicon about 25% smaller than the original amplicon. This difference, however, was not reflected in differences in band density; the relative abundance of the coamplified products remained reasonably constant with increasing numbers of amplification cycles.
The cPCR was compared with conventional serial target dilution, which is often used for PCR quantita-tion. 16 Serial target dilution is useful, but because of the large number of dilutions and reactions required, it is labor and reagent intensive, time consuming, and error prone. Moreover, the serial dilution method cannot yield quantitative results on unpurified samples because of the undefined composition of the samples. Data from this study showed that the 2 assays were in general agreement, with the cPCR having a somewhat greater sensitivity.
Upon application to a limited number of field samples, the cPCR worked well in a variety of species, including moose, deer, bison, cattle and sheep. A wide range in copy number of target DNA was observed among individuals. Samples from clinically affected animals usually contained higher levels of viral DNA than did samples from either latently infected clinically susceptible animals or carrier animals. For example, DNA from the PBLs of a moose with severe clinical MCF contained almost 1 ϫ 10 8 copies of viral DNA per 2 g DNA, whereas the sample from a latently infected, clinically normal moose from the same captive herd contained only about 300 copies (data not shown). This finding could suggest the possibility that quantitation of virus in peripheral blood may be of some predictive value for monitoring latently infected clinically susceptible ruminants. However, too little data are yet available to draw firm conclusions on the relationships among viral load, tissues, clinical status, and species.
The cPCR assay should also be useful for epidemiologic studies in carrier species. When samples from a 7-month-old infected sheep were examined, about 400 times as much viral DNA per microgram of total DNA was found in the nasal secretions as was present in the PBLs, suggesting enhanced viral replication in the nasal, pharyngeal, or perhaps ocular epithelium. This finding is consistent with recent detection of viral DNA in a significant number of lambs of about the same age raised under normal flock conditions. 7 This assay should facilitate the rigorous quantitative studies of the sequential distribution of the virus in various tissues and cellular subpopulations that are needed to arrive at a coherent picture of the pathogenesis of this poorly understood disease.
